06:02 PM EST, 11/18/2025 (MT Newswires) -- Eledon Pharmaceuticals ( ELDN ) said Tuesday that preliminary data from six type 1 diabetes patients treated with its investigational drug tegoprubart after islet transplantation showed all achieved insulin independence, with some maintaining insulin-free status for over 15 months.

Hemoglobin A1C levels were sustained in a healthy range, and the drug was generally well tolerated, with no serious infections, rejection events, or kidney toxicity reported.

The investigator-initiated trial at UChicago Medicine is still ongoing and funded by Breakthrough T1D, which has also committed to supporting a second study. The preliminary results were presented at the Rachmiel Levine-Arthur Riggs Diabetes Research Symposium in Los Angeles.

Shares of Eledon rose 5.2% in after-hours trading.